- Home
- RVSB vs IMUX Comparison
RVSB vs IMUX Comparison
Compare RVSB & IMUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RVSB
- IMUX
- Stock Information
- Founded
- RVSB 1923
- IMUX 2016
- Country
- RVSB United States
- IMUX United States
- Employees
- RVSB N/A
- IMUX N/A
- Industry
- RVSB Savings Institutions
- IMUX Biotechnology: Pharmaceutical Preparations
- Sector
- RVSB Finance
- IMUX Health Care
- Exchange
- RVSB Nasdaq
- IMUX Nasdaq
- Market Cap
- RVSB 107.6M
- IMUX 92.2M
- IPO Year
- RVSB 1993
- IMUX N/A
- Fundamental
- Price
- RVSB $5.34
- IMUX $0.75
- Analyst Decision
- RVSB Buy
- IMUX Strong Buy
- Analyst Count
- RVSB 1
- IMUX 5
- Target Price
- RVSB $7.00
- IMUX $7.00
- AVG Volume (30 Days)
- RVSB 49.2K
- IMUX 1.3M
- Earning Date
- RVSB 10-28-2025
- IMUX 11-06-2025
- Dividend Yield
- RVSB 1.46%
- IMUX N/A
- EPS Growth
- RVSB 361.12
- IMUX N/A
- EPS
- RVSB 0.22
- IMUX N/A
- Revenue
- RVSB $52,756,000.00
- IMUX N/A
- Revenue This Year
- RVSB $10.25
- IMUX N/A
- Revenue Next Year
- RVSB $11.23
- IMUX N/A
- P/E Ratio
- RVSB $24.91
- IMUX N/A
- Revenue Growth
- RVSB 12.87
- IMUX N/A
- 52 Week Low
- RVSB $4.74
- IMUX $0.56
- 52 Week High
- RVSB $6.59
- IMUX $1.42
- Technical
- Relative Strength Index (RSI)
- RVSB 56.52
- IMUX 43.53
- Support Level
- RVSB $5.27
- IMUX $0.67
- Resistance Level
- RVSB $5.60
- IMUX $0.87
- Average True Range (ATR)
- RVSB 0.16
- IMUX 0.05
- MACD
- RVSB 0.02
- IMUX 0.00
- Stochastic Oscillator
- RVSB 66.05
- IMUX 37.84
About RVSB Riverview Bancorp Inc
Riverview Bancorp Inc is an American savings and loan holding company. The company through its subsidiaries engages in the business of attracting deposits and puts it to use in its market area to originate commercial business. It is organized into two operating segments, Banking Operations performed by the bank and trust and Investment Services performed by the Trust company. The company products and services include checking, saving, money market, mortgage, home equity, consumer, online banking, cash management, and others.
About IMUX Immunic Inc.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.